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Steroid-induced elevated intraocular pressure (IOP) leading to glaucoma is a well-documented 
phenomenon(1). However, iCorticosteroid can cause a rise in IOP within a few weeks of 
commencement, but typically the pressures return to normal on cessation of treatment. Intra-
articular corticosteroid injection causing elevated IOP is an extremely rare phenomenon , but 
has been previously documented in the literature(2, 3). To our knowledge, wWe describe 
present the firsta case of of a patient who received intra-articular glucocorticoids resulting in 
steroid-induced glaucoma. high IOP and permanent glaucomatous damage. 
 
A 56-year-old male received multiple cervical spine facet joint injections of corticosteroid on 
5 different occasions for cervical radiculopathy and referred shoulder pain secondary to a work-
related injury over a 17-month period.  Approximately 6 months after his 5th and final 
corticosteroid injection, he the patient presented with noted symptoms of blurred vision in the 
right eye.  (RE) with associated frontal headache. He had no previous personal or family history 
of glaucoma and optometric visits prior to corticosteroid treatment had recorded no ocular 
pathology. his IOP at the optometrist office previously were reported normal. On ophthalmic 
examination his visual acuities werey were RE 6/19 OD and Left Eye (LE) 6/6 OS. There was 
a right relative afferent pupillary defect, and the Goldmann tonometry revealed an IOP with 
Goldmann applanation tonometry was  of RE 55mmHg OD and LE 31mmHg OS.  There was 
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a relative afferent pupillary defect (RAPD) in the RE. Corneal thicknesses were within normal 
limits. Gonioscopy demonstrated bilateral open angles and there were no features of any other 
secondary glaucoma. . The anterior segment examination was unremarkable in both eyes. 
Fundoscopic examination revealed complete pathological cupping of the right optic disc and a 
0.8 cupping cup-disc ratio on the left. (Fig.ure 1). Automated perimetry showed Visual field 
showed severe significant field constriction in the RE and a moderate glaucomatous lesser 
degree of loss in the left eye LE (Figgure 2). OCT scanning elicited significant thinning of 
retinal nerve fiber layer (RNFL) layers worse in the RE than the LE. He was immediately 
commenced started onon maximal medical IOP-pressure lowering therapy including oral 
acetazolamide.  Diamox, Simbrinza (brinzolamide / brimonidine tartarate) and Duotrav 
(Travoprost/ Timolol) to control the IOP. 
 
 
Within daysOne week later, his IOP in both eyes was in the low teens. had normalized to RE 
Acetazolamide13mmHg and LE 14mmHg. Diamox wa was discontinued and the IOP remained 
at target pressurestable on topical medical therapy. with Simbrinza and Duotrav eye drops. It 
is highly likely speculated that othat this ur patient developed developed steroid-induced 
elevated IOP which progressed to glaucoma from the multiple intra-articular glucocorticoid 
injections.. 
 
The pathophysiology of steroid use is well documented. Glucocorticoids, secreted by the 
adrenal glands were first discovered in the 1940s and were used for their anti-inflammatory 
properties. As the therapeutic use of glucocorticoids became more commonplace, possible 
side-effects were also discovered such as the development of ocular hypertension in certain 
individuals. Becker et al. showed that in a normal population there are three categories of 
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steroid responders: s. 6% of individuals were high responders with a rise of >15mmHg in IOP 
after ocular steroid usage 4-6 weeks after initiation; m. Moderate responders had 6-15mmHg 
IOP rise, and non-responders had < 6mmHg elevation(4). Additional risks that contributes to 
high- steroid response includes , diabetes, primary open- angle glaucoma (POAG) sufferers 
andand family history of  relatives of those with primary open angle glaucoma (POAG). There 
is considerable evidence to support the concept that corticosteroids increase the aqueous 
outflow resistance by altering the extracellular matrix composition of the trabecular meshwork, 
(5) and there is evidence for genetic susceptibility. However, the individualized IOP response 
to steroids remains poorly understood. W 
 
It is generally accepted that steroid induced elevated IOP is a direct result of altering trabecular 
meshwork (TM) ultrastructure. Firstly, there is a dysregulation and excessive extracellular 
matrix deposition in the cribriform region and adjacent trabecular beam. Steroid activate Cross-
linked actin cytoskeleton (also known as CLANS), precursors to stress fibers which can link 
across TM structure and activate to reduce overall aqueous outflow and increase IOP. In 
addition, steroid cause increased accumulation of basement membrane like material deposited 
in the outer trabecular meshwork beams. Immunohistology shows these cells to have 
characteristics of myofibroblasts, cells strongly associated with fibrosis. This change in the TM 
ultrastructure is unique to the eyes with steroid induced glaucoma (SIG) and is not seen in 
aging eyes or those eyes with POAG(5).  
 
Glucocorticoid controls gene expression for inflammation and complement activation and its 
response varies considerably from individual to individual. The initiation of this effect is via 
the glucocorticoid receptor, which is genetically encoded by gene NR3CQ. This receptor 
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resides intracellularly alongside of the multiprotein complex which includes chaperone 
proteins and immunophilins.  The primary goal of glucocorticoid is to control gene expression.  
 
Myocilin (MYOC) is also known as the trabecular meshwork-inducible glucocorticoid 
response (TIGR) gene product isolated by Polansky and Colleagues as a gene candidate for the 
outflow obstruction/regulation in glaucoma. The expression of MYOC in trabecular meshwork 
has been shown to be steroid-induced. This gene and its mutations are charted into a database 
online and accounts for 4-5% of POAG. It is hoped that this may provide insight into idiopathic 
POAG and other causative genes. Further studies could provide a definitive answer to the 
question about whether MYOC protein plays any role in SIG(5). 
 
We hope that genetic profiling in precision medicine of Ophthalmology may protect the steroid 
responsive patients in the future by tailoring medical treatment to fit the characteristics of the 
individual patient. Before that is a reality, we recommend that clinicians physicians and 
surgeons communicommunicate the risk of elevated IOP intraocular pressure to patients 
receiving repeated intra-articular corticosteroid injections. and consider baseline and ongoing 
oOphthalmic examination whilst receiving treatment.  is also recommended in these patients 
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Figure 2: Figure showing the Humphrey Visual Field Defect in the Right and left eye 
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